Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial ...
Welcome to the Rani Fourth Quarter and Full Year 2025 Financial Results and Corporate Update Conference Call. [Operator Instructions] As a reminder, this call is being recorded today, March 26, 2026.
Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company ...
The consensus estimate for Q4 2025 revenue is $0.01 billion, and the earnings are expected to come in at -$0.06 per share.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results